Overall Technical outlook

Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Revenue projections:

Revenue projections for ELV
The projected decline in ELV's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.469000
forwardPE 14.194724
debtToEquity 68.663000
earningsGrowth 0.179000
revenueGrowth 0.014000
grossMargins 0.264320
operatingMargins 0.039770
trailingEps 23.570000
forwardEps 30.285900

ELV's current ratio of 1.469 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. ELV's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
ELV's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
ELV's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for ELV
The price of ELV has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for ELV

ELV had 5 sell transactions, while the market price was at 356.2551025390625 per share.2 purchases of ELV stock were recorded, with market price of 328.91741943359375 per share.The transactions conducted by insiders don't suggest any significant movement or clear trend, leaving the overall direction of the company uncertain.

Recommendation changes over time:

Recommendations trend for ELV

Analysts' buy bias toward Elevance Health, Inc. suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Elevance Health, Inc. is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.